<?xml version='1.0' encoding='utf-8'?>
<document id="28385544"><sentence text="A Prediction Method for P-glycoprotein-Mediated Drug-Drug Interactions at the Human Blood-Brain Barrier From Blood Concentration-Time Profiles, Validated With PET Data." /><sentence text="The purpose of this study was to establish physiologically based pharmacokinetic models to predict in humans the brain concentration-time profiles and P-glycoprotein (Pgp)-mediated brain drug-drug interactions between the model Pgp substrate (R)-[11C]verapamil (VPM), the model dual Pgp/breast cancer resistance protein (BCRP) substrate [11C]tariquidar (TQD), and the Pgp inhibitor tariquidar"><entity charOffset="242-260" id="DDI-PubMed.28385544.s2.e0" text="(R)-[11C]verapamil" /><entity charOffset="262-265" id="DDI-PubMed.28385544.s2.e1" text="VPM" /><pair ddi="false" e1="DDI-PubMed.28385544.s2.e0" e2="DDI-PubMed.28385544.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28385544.s2.e0" e2="DDI-PubMed.28385544.s2.e1" /></sentence><sentence text=" The model predictions were validated with results from positron emission tomography studies in humans" /><sentence text=" Using these physiologically based pharmacokinetic models, the differences between predicted and observed areas under the concentration-time curves (AUC) of VPM and TQD in the brain were within a 1"><entity charOffset="157-159" id="DDI-PubMed.28385544.s4.e0" text="VPM" /></sentence><sentence text="2-fold and 2" /><sentence text="5-fold range, respectively" /><sentence text=" Also, brain AUC increases of VPM and TQD after Pgp inhibitor administration were predicted with 2"><entity charOffset="30-32" id="DDI-PubMed.28385544.s7.e0" text="VPM" /></sentence><sentence text="5-fold accuracy when inÂ vitro inhibition constant or half-maximum inhibitory concentration values of tariquidar were used" /><sentence text=" The predicted rank order of the magnitude of AUC increases reflected the results of the clinical positron emission tomography studies" /><sentence text=" Our results suggest that the established models can predict brain exposure from the respective blood concentration-time profiles and rank the magnitude of the Pgp-mediated brain drug-drug interaction potential for both Pgp and Pgp/BCRP substrates in humans" /><sentence text="" /></document>